Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00634231
Recruitment Status : Completed
First Posted : March 12, 2008
Last Update Posted : November 2, 2021
Boston Children's Hospital
Information provided by (Responsible Party):
Candel Therapeutics, Inc.

Brief Summary:
This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in combination with radiation therapy. The primary objective is to determine if this approach is safe and can be effectively delivered without disturbing standard therapy.

Condition or disease Intervention/treatment Phase
Malignant Glioma Recurrent Ependymoma Biological: AdV-tk Drug: valacyclovir Radiation: Radiation Phase 1

Detailed Description:
This is an Open label, Phase I, dose escalation study. Patients will receive an injection of AdV-tk into the tumor or tumor bed during the surgical procedure followed by 14 days of anti-herpetic prodrug, valacyclovir, starting 1-3 days after vector injection. Standard radiotherapy will begin 3-7 days after AdV-tK injection. Standard chemotherapy may begin after completion of valacyclovir at the discretion of the treating physician and family. Two dose levels of AdV-tk will be evaluated with a fixed dose of valacyclovir.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Actual Study Start Date : October 2010
Actual Primary Completion Date : December 2015
Actual Study Completion Date : June 2021

Arm Intervention/treatment
Experimental: AdV-tk
AdV-tk + valacyclovir in combination with standard of care radiation
Biological: AdV-tk
Drug: valacyclovir
Other Name: Prodrug

Radiation: Radiation
Other Name: Radiation therapy

Primary Outcome Measures :
  1. Safety based on standard laboratory and clinical adverse event monitoring [ Time Frame: 2 months ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 5 years ]
  2. Progression-free survival [ Time Frame: 5 years ]
  3. Objective tumor response [ Time Frame: 5 years ]
  4. Immunologic function [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be 3 years of age or older
  • Patients must be planning to undergo standard of care treatment with surgery and radiation therapy.
  • Patients must have malignant glioma or recurrent ependymoma
  • Tumor must be accessible for injection and must not be located in the brainstem or deep midbrain
  • Performance Score: Karnofsky ≥60% if >10y/o, Lansky ≥60 if ≤10y/o
  • Bone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral absolute neutrophil count ≥ 1000/µl, platelet count ≥ 100,000/µl (transfusion independent) and hemoglobin ≥ 8.0 gm/dL
  • Renal Function: Patients must have serum creatinine ≤ 1.5 times upper limit of institutional normal for age and/or GFR ≥ 70 mL/min/1.73 m2.
  • Hepatic Function: Bilirubin ≤ 1.5 times institutional normal; SGPT (ALT) < 3 times institutional normal
  • Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked prior to enrollment and clinically significant abnormalities corrected prior to surgery/AdV-tk injection
  • Patients with seizure disorder may be enrolled if well controlled
  • Signed informed consent according to institutional guidelines must be obtained

Exclusion Criteria:

  • Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection
  • Patients on immunosuppressive drugs (with exception of corticosteroid)
  • Known history of HIV or underlying immunodeficiency
  • Patients with acute infections (viral, bacterial or fungal infections requiring therapy)
  • Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy
  • Other serious co-morbid illness or compromised organ function
  • No other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from study entry until tumor progression)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00634231

Layout table for location information
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)
Chicago, Illinois, United States, 60611
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Candel Therapeutics, Inc.
Boston Children's Hospital
Publications of Results:
Layout table for additonal information
Responsible Party: Candel Therapeutics, Inc. Identifier: NCT00634231    
Obsolete Identifiers: NCT00729105
Other Study ID Numbers: 07-098
First Posted: March 12, 2008    Key Record Dates
Last Update Posted: November 2, 2021
Last Verified: October 2021
Keywords provided by Candel Therapeutics, Inc.:
Malignant glioma
Glioblastoma multiforme
Anaplastic astrocytoma
Recurrent ependymoma
Gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antiviral Agents
Anti-Infective Agents